NEW YORK, July 17, 2026, 07:00 EDT
- Iovance Biotherapeutics NASDAQ:IOVA gained 10.2% between July 10 and the close on Thursday.
- SPDR S&P Biotech ETF (NYSEARCA:XBI) dropped 4.4%. The Nasdaq Biotechnology Index (INDEXNASDAQ:NBI) declined 1.5%.
- The full-year outlook suggests quarterly revenue in the second half will range from $95.8 million to $105.8 million.
Iovance finished Thursday at $4.66, gaining 10.2% from July 10. Nasdaq’s regular session had ended at the dateline, while premarket trading remained open.
The advance was notable as wider biotechnology indices declined over the same four sessions.
The change is significant as meeting full-year guidance demands a quicker sales rate. According to company data, revenue for the second half needs to be between $191.6 million and $211.6 million.
That amounts to $95.8 million to $105.8 million each quarter. The range stands 10.1% to 21.6% higher than the midpoint of second-quarter guidance.
| Security | July 10 close | July 16 close | Change |
|---|---|---|---|
| Iovance Biotherapeutics NASDAQ:IOVA | $4.23 | $4.66 | up 10.2% |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | $159.03 | $152.00 | down 4.4% |
| Nasdaq Biotechnology Index (INDEXNASDAQ:NBI) | 6,644.35 | 6,546.81 | off 1.5% |
Data reflect closing figures from July 10 to July 16.
Iovance shares surged 20.6% on Wednesday, with volume reaching 43.6 million—almost triple the usual amount. The stock then declined 1.7% on Thursday.
The company’s last press release was on June 19, and its latest 8-K filing occurred on July 2.
The lack of that presence makes short covering a credible driver, but it does not determine the cause.
As of June 30, short interest totaled 100.5 million shares, equal to 24.4% of the float and covering 7.1 trading days.
Management is basing its operations strategy on Amtagvi. “We are accelerating Amtagvi’s adoption and commercial rollout following record demand,” interim CEO Frederick Vogt said in May.
Revenue for the first quarter reached $71.43 million, an increase of roughly 45% from a year earlier. Amtagvi accounted for $60.22 million, while Proleukin generated $11.21 million. The gross margin stood at 41%.
Iovance reported a loss of $79.0 million and spent $72.1 million in operating cash. The company’s cash reserves of about $319 million are projected to support operations through well into 2028.
The coming week provides a clearer look at market positioning. FINRA is set to release July 15 short-interest figures on July 24, covering the day of Wednesday’s rally.
Iovance has no investor events scheduled. As a result, attention in the short term will be on trading activity instead of anticipated company updates.
Risks: Amtagvi sales are contingent on patient health and the ability of manufacturing batches to meet required standards. Iovance raised $98.5 million in the first quarter via stock sales, underscoring potential dilution risk.
The July 24 figures can assess the positioning thesis. Upcoming financial results will need to evaluate the sales thesis.
